

Tirzepatide is a groundbreaking medical weight management medication that targets both GIP and GLP-1 receptors — making it one of the most powerful dual-action weight loss treatments available. Marketed as Zepbound for weight management and Mounjaro for diabetes, tirzepatide weight loss results in clinical trials have been remarkable, with some patients achieving up to 22% body weight reduction.
Tirzepatide is part of our medically supervised weight loss program and offers an advanced alternative to semaglutide GLP-1 weight loss injections for patients seeking maximum results.
Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide activates both GIP and GLP-1 pathways simultaneously. This dual-action weight loss mechanism provides:
Both Mounjaro/Zepbound and Ozempic/Wegovy are excellent medical weight loss options. In head-to-head studies, tirzepatide has shown greater average weight loss. However, individual responses vary — some patients respond better to one medication over the other. Sarah will evaluate your health history, metabolism, and goals to recommend the best fit.
Tirzepatide is administered as a once-weekly subcutaneous injection. Dosing starts low and increases gradually to minimize side effects like nausea, which typically improve as your body adjusts. Most patients notice reduced appetite and the beginning of weight loss within the first few weeks, with significant results building over months of consistent medical weight management.
Our medical weight loss program pairs tirzepatide weight loss injections with ongoing monitoring, dosage optimization, and lifestyle coaching. Many patients find that reaching their weight loss goals inspires them to explore complementary aesthetic treatments — from injectable treatments for facial rejuvenation to laser services for skin improvement. Sarah takes a holistic approach, supporting your transformation from the inside out.
Tirzepatide is part of our weight loss treatments at Sarah Hitchcox Aesthetics in Knoxville and Farragut, TN. Browse our full range of services to find the right treatment for your goals.
Targets both GIP and GLP-1 receptors for enhanced weight loss results.
Clinical trials showed up to 22% body weight reduction in some patients.
Simple once-weekly injection that fits easily into your routine.
Tirzepatide targets both GIP and GLP-1 receptors, while semaglutide targets only GLP-1. This dual action may lead to greater weight loss for some patients. Both are administered as weekly injections.
Results vary by individual, but clinical trials showed average weight loss of 15-22% of body weight over 72 weeks at the highest doses.
The most common side effects are nausea, diarrhea, and decreased appetite, which typically improve as your body adjusts. Starting at a low dose and gradually increasing helps minimize these effects.
Yes. Mounjaro is the brand name for tirzepatide when prescribed for diabetes, and Zepbound is the brand name when prescribed specifically for weight management. The active ingredient is the same.
5113 Kingston Pike Suite 15, Knoxville, TN 37919
Get Directions102 S Campbell Station Rd Suite 8, Knoxville, TN 37934
Get Directions(865) 214-7238
sarah@hitchcoxaesthetics.com